Dallas, Tx – May 3, 2017 – North American Cannabis Holdings, Inc. (USOTC: USMJ) and Puration, Inc. (USOTC: PURA) are set to be named in a major announcement tomorrow scheduled for release at 11 AM EST.
“The announcement tomorrow has been in the works for some time,” said Steven Rash, CEO of North American Cannabis Holdings. “Going forward USMJ will solidify its leadership position within the growing legal cannabis sector.”
“Puration’s success with EVERx, ML Capital Group and Spanish Peaks has served as a catalyst to moving forward what will be announced tomorrow,” added Brian Shibley, CEO of Puration. “After tomorrow, you can expect a groundswell of new product production, contracts and merger and acquisition transactions.“
USMJ began development within the emerging legal cannabis sector in 2013. The Company has amassed substantial market experience and develop a number of cannabis industry operating assets. Nearly two years ago, the concept company reported its first revenue and today the company is on the verge of reporting its first profits. USMJ spun off one of its cannabis operating assets, a cannabis extraction business, into PURA and now PURA has reported its first revenues. Tomorrow’s announcement will be the introductory paragraph in a new exciting chapter of the two companies ongoing growth within the emerging legal cannabis sector.
Learn More About USMJ: growusmj.com
Learn More About PURA: purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Brian Shibley, CEO
North American Cannabis Holdings Contact: